Why the study?
High dose interleukin-2 is known to cause cardiopulmonary toxicity, but its effects on cardiopulmonary structure and function required evaluation.
Does high dose interleukin-2 therapy cause cardiopulmonary structural and functional changes in patients?
Population
7 patients receiving high dose IL-2 therapy and 10 healthy volunteers
Comparison
High dose IL-2 therapy vs healthy volunteers
Design
Observational magnetic resonance imaging study
Authors
Loading...
May warrant cardiac monitoring during IL-2 therapy; leaves open whether fibrosis is preventable or reversible.
Does high dose interleukin-2 therapy cause cardiopulmonary structural and functional changes in patients?
High dose IL-2 therapy causes acute cardiopulmonary inflammation and reversible LV dysfunction, but leads to chronic LV hypertrophy and myocardial fibrosis.
Lagan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: